^
Association details:
Biomarker:BRAF mutation
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations

Published date:
09/30/2023
Excerpt:
Data of aNSCLC patients treated with IO or CT-IO in any line from January 2016 to September 2022 were retrospectively collected….Within the m-cohort, BRAF atypical mutations had the better outcomes (Overall Response Rate [ORR], PFS)…
Secondary therapy:
Chemotherapy
DOI:
10.1016/j.cllc.2023.08.004
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1071P - Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients

Published date:
09/05/2022
Excerpt:
CONTRADICTING EVIDENCE: Among 480 advanced NSCLC patients (pts) treated with IO at Istituto Nazionale Tumori of Milan, 113 pts who performed cell-free DNA sequencing....PD-L1 positively correlated with DCR, ORR and OS. Among the G features, SHAP detected TP53 as the most relevant gene negatively correlated with outcome. KIT gene was identified as the second most important gene negatively correlated with the outcomes. BRAF was found to correlate with worse response....The explainable AI algorithms suggested a negative predictive role of TP53 and KIT mutational status.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).

Published date:
05/16/2018
Excerpt:
ICI has inconstant efficacy in NSCLC harboring activating mutation. KRAS, BRAF and MET-exon 14 patients derive a greater benefit than EGFR, ALK and RET patients
DOI:
10.1200/JCO.2018.36.15_suppl.9010